Clinical Trial Update: A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of Fluticasone Furoate combined with GW642444 inhalation powder in chronic obstructive pulmonary disease; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Furoate (fluticasone furoate)
• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2013-08-15